Want to see DE:LXS full AI Analyst Report?
Top Page
LANXESS
(XETRA:LXS)
Select Model
Select Model
Rating:48Neutral
Price Target:
€11.50
▼(-20.63% Downside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weak financial performance (losses and negative profitability) and a bearish technical trend (price below key moving averages with subdued momentum). These are partially offset by improving operational momentum and reaffirmed guidance from the latest earnings call, plus a supportive dividend yield despite loss-driven negative P/E.
Positive Factors
Operational recovery and reaffirmed guidance
The sharp sequential improvement in sales, EBITDA and free cash flow indicates recovering operating momentum across the business. Reaffirmed full-year guidance and a defined Q3 EBITDA range also provide evidence that management sees the improvement as sufficiently durable to support near-term execution.
Negative Factors
Persistent losses and weak profitability
Continuing operating and net losses indicate that the recent recovery has not yet restored sustainable profitability. Thin margins and the reversal from earnings in 2021–2022 to losses since 2024 leave earnings power vulnerable to cyclical pressure and limit internally generated capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Operational recovery and reaffirmed guidance
The sharp sequential improvement in sales, EBITDA and free cash flow indicates recovering operating momentum across the business. Reaffirmed full-year guidance and a defined Q3 EBITDA range also provide evidence that management sees the improvement as sufficiently durable to support near-term execution.
Read all positive factors
LANXESS (LXS) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.01B
Dividend Yield0.85%
Average Volume (3M)571.99K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth-9.81%
EPS Growth-305.46%
CountryDE
Employees11,495
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)-7.75
Shares Outstanding86,346,306
10 Day Avg. Volume534,082
30 Day Avg. Volume571,991
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.27
P/FCF Ratio-27.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.88Price Target Upside-11.09% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering7
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€5.76B
LANXESS Business Overview & Revenue Model
Company Description
LANXESS Aktiengesellschaft, a prominent specialty chemicals firm, is engaged worldwide in the development, production, and sale of chemical intermediates, additives, specialized chemicals, and plastics. The company's operations are divided into fo...
How the Company Makes Money
LANXESS makes money primarily by selling specialty chemical products and solutions to industrial customers under a business-to-business model. Revenue is generated from (1) product sales of chemical intermediates and specialty additives (sold by v...
LANXESS Earnings Call Summary
Earnings Call Date:Aug 07, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful operational recovery and sequential momentum: sales and prices improved (sales +6% year-over-year, prices +3%, sales +13% sequential), EBITDA rose strongly quarter-on-quarter (management cited ~62% sequential improvement), free cash flow turned positive, and full-year guidance was reaffirmed. However, material near-term risks remain, especially logistics disruptions from very low Rhine water levels (single-digit million incremental costs so far but potential for greater impact), FX headwinds from a weak dollar, and continued competitive pressure from Asia. Management emphasized early mitigation actions and maintained a cautious outlook despite strong Q2 performance.Positive Updates
Year-over-Year Sales Increase
Sales increased by ~6% versus the prior year, driven by positive volume and price effects.
Negative Updates
Low Rhine Water Levels and Logistics Risk
Severely low Rhine water levels reduced barge loading capacity to ~20–30% per vessel and rendered some loading/unloading points inaccessible, creating logistics challenges and elevated risk of production disruption if prolonged.
Read all updates
Q2-2026 Updates
Positive
Negative
Year-over-Year Sales Increase
Sales increased by ~6% versus the prior year, driven by positive volume and price effects.
Read all positive updates
Company Guidance
LANXESS confirmed its full‑year 2026 guidance and reported several key metrics: year‑on‑year sales were up about 6 percentage points, selling prices rose ~3%, and Q2 sales jumped 13% sequentially; EBITDA “substantially increased” (management cited roughly a 62% uplift vs. the prior quarter and said Q2 beat its guidance), Q2 delivered a clearly positive free cash flow (unusual for H1), and management expects Q3 results in the range of EUR 130–150 million; COVID‑unrelated logistics headwinds from low Rhine water added single‑digit million costs to date and investments to improve flexibility were in the upper single‑digit million range, while NRW inbound volumes are ~400 ktpa.LANXESS Financial Statement Overview
Summary
Income Statement
37
Negative
Balance Sheet
56
Neutral
Cash Flow
49
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.54B | 5.67B | 6.37B | 6.71B | 8.09B | 7.56B |
| Gross Profit | 1.07B | 1.13B | 1.30B | 1.27B | 1.94B | 1.84B |
| EBITDA | 541.00M | 497.00M | 549.00M | -143.00M | 875.00M | 684.00M |
| Net Income | -669.00M | -577.00M | -177.00M | 443.00M | 185.00M | 267.00M |
Balance Sheet | ||||||
| Total Assets | 8.35B | 8.09B | 9.71B | 9.66B | 11.29B | 10.52B |
| Cash, Cash Equivalents and Short-Term Investments | 1.07B | 497.00M | 615.00M | 496.00M | 403.00M | 1.23B |
| Total Debt | 2.98B | 2.53B | 3.06B | 3.06B | 4.23B | 3.48B |
| Total Liabilities | 4.87B | 4.59B | 5.12B | 5.16B | 6.86B | 6.76B |
| Stockholders Equity | 3.48B | 3.50B | 4.59B | 4.50B | 4.42B | 3.76B |
Cash Flow | ||||||
| Free Cash Flow | 59.00M | -56.00M | 188.00M | 512.00M | -248.00M | -72.00M |
| Operating Cash Flow | 373.00M | 263.00M | 508.00M | 838.00M | 159.00M | 407.00M |
| Investing Cash Flow | -582.00M | 389.00M | -263.00M | 423.00M | -1.05B | -432.00M |
| Financing Cash Flow | 417.00M | -518.00M | -97.00M | -1.47B | 613.00M | 389.00M |
LANXESS Technical Analysis
Negative
14.49
Price Trends
13.37
Negative
14.55
Negative
15.93
Negative
Market Momentum
-0.42
Positive
36.53
Neutral
7.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:LXS, the sentiment is Negative. The current price of 14.49 is above the 20-day moving average (MA) of 12.37, above the 50-day MA of 13.37, and below the 200-day MA of 15.93, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 36.53 is Neutral, neither overbought nor oversold. The STOCH value of 7.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:LXS.
LANXESS Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €5.44B | 17.18 | 17.00% | 3.19% | 5.53% | 17.05% | |
64 Neutral | €9.91B | 82.21 | 1.49% | 4.70% | -4.03% | -71.46% | |
62 Neutral | €9.00B | 24.73 | 8.30% | 3.05% | -5.28% | -13.76% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
53 Neutral | €4.13B | -9.42 | -11.14% | 3.04% | ― | ― | |
50 Neutral | €12.56B | -23.82 | -7.29% | 8.18% | -8.72% | -140.66% | |
48 Neutral | €1.01B | -1.51 | -18.62% | 0.85% | -9.81% | -305.46% |
* Basic Materials Sector Average
DE:LXS
LANXESS
11.73
-8.99
-43.39%
DE:BNR
Brenntag AG
62.32
15.45
32.98%
DE:1COV
Covestro
60.50
0.66
1.10%
DE:EVK
Evonik
21.26
7.41
53.48%
DE:FPE
Fuchs Petrolub
38.30
9.38
32.45%
DE:WCH
Wacker Chemie AG
83.15
14.40
20.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.